Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · IEX Real-Time Price · USD
6.54
-0.42 (-6.03%)
Apr 24, 2024, 4:00 PM EDT - Market closed
Cogent Biosciences Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Cogent Biosciences stock have an average target of 16.25, with a low estimate of 8.00 and a high estimate of 26. The average target predicts an increase of 148.47% from the current stock price of 6.54.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 27, 2024.
Analyst Ratings
The average analyst rating for COGT stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 3 | 4 | 4 | 2 | 2 | 2 |
| Hold | 0 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $18 → $20 | Buy | Maintains | $18 → $20 | +205.81% | Feb 27, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $11 → $13 | Strong Buy | Maintains | $11 → $13 | +98.78% | Feb 26, 2024 |
| Baird | Baird | Buy → Hold Downgrades $14 → $8 | Buy → Hold | Downgrades | $14 → $8 | +22.32% | Feb 26, 2024 |
| Needham | Needham | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +175.23% | Feb 26, 2024 |
| Wedbush | Wedbush | Hold Maintains $5 → $10 | Hold | Maintains | $5 → $10 | +52.91% | Feb 23, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.35M
EPS This Year
-2.04
from -2.42
EPS Next Year
-2.03
from -2.04
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 11.1M | 228.9M | 686.6M | 615.8M |
| Avg | n/a | 1.4M | 86.2M | 396.8M | 598.2M |
| Low | n/a | n/a | 6.2M | 242.3M | 574.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 16,830.5% | 697.0% | 55.2% |
| Avg | - | - | 6,272.0% | 360.6% | 50.8% |
| Low | - | - | 360.1% | 181.2% | 44.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -1.48 | -1.46 | -1.03 | 1.14 |
| Avg | -2.04 | -2.03 | -1.49 | 0.86 |
| Low | -2.37 | -2.65 | -2.35 | 0.58 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | - |
| Avg | - | - | - | - |
| Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.